Potential impact of renin-angiotensin system inhibitors and calcium channel blockers on plasma high-molecular-weight adiponectin levels in hemodialysis patients

Hypertension Research

Volumn 34, Issue 5, 2011, Pages 592-598

  Nakagawa, Naoki ^a   Yao, Naoyuki ^b   Hirayama, Tomoya ^b   Ishida, Mari ^b   Ishida, Hironori ^b   Wada, Atsushi ^c   Fujino, Takayuki ^a   Saijo, Yasuaki ^a   Kikuchi, Kenjiro ^a   Hasebe, Naoyuki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b Kitasaito Hospital   (Japan)

^c ASAHIKAWA RED CROSS HOSPITAL   (Japan)

Author keywords

calcium channel blockers; hemodialysis patients; high molecular weight adiponectin; renin angiotensin system inhibitors; visceral obesity

Indexed keywords

ADIPONECTIN; CALCIUM CHANNEL BLOCKING AGENT; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEMODIALYSIS; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; REGRESSION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; TRIGLYCERIDES;

EID: 79955624003     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.282     Document Type: Article

References (34)

1. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 550-562.
2. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615. (Pubitemid 29297538)
3. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450. (Pubitemid 36993340)
4. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33. (Pubitemid 38082408)
5. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y, Osaka CADSG. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89. (Pubitemid 36091630)
6. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141. (Pubitemid 34042020)
7. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451. (Pubitemid 40686653)
8. Daugirdas JT. 2nd-generation logarithmic estimates of single-pool variable volume Kt/ V-an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213.
9. Ebinuma H, Miyazaki O, Yago H, Hara K, Yamauchi T, Kadowaki T. A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta 2006; 372: 47-53. (Pubitemid 44286756)
10. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239. (Pubitemid 38924592)
11. Matsuzawa Y, Nakamura T, Takahashi M, Ryo M, Inoue S, Ikeda Y, Ohno M, Sakata T, Fukagawa K, Saitoh Y, Sato Y, Shirai K, Miyazaki S, Tokunaga K, Yamanouchi K, Shibasaki T, Nagai M. New criteria for 'obesity disease' in Japan. Circ J 2002; 66: 987-992. (Pubitemid 35416333)
12. Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transpl 2007; 22: 171-178. (Pubitemid 46050342)
13. Shoji T, Shinohara K, Hatsuda S, Kimoto E, Fukumoto S, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 2005; 54: 330-334. (Pubitemid 40250092)
14. Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004; 43: 1047-1055.
15. Komaba H, Igaki N, Goto S, Yokota K, Doi H, Takemoto T, Kohno M, Hirosue Y, Goto T. Increased serum high-molecular-weight complex of adiponectin in type 2 diabetic patients with impaired renal function. Am J Nephrol 2006; 26: 476-482. (Pubitemid 44971739)
16. Odamaki M, Furuya R, Kinumura Y, Ikegaya N, Kumagai H. Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients. Nephron Clin Pract 2006; 102: C8-C13. (Pubitemid 43250927)
17. Adamczak M, Rzepka E, Chudek J, Wiecek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol 2005; 62: 114-118. (Pubitemid 40175291)
18. Kopple JD, Zhu XF, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56: 1136-1148. (Pubitemid 29411743)
19. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808. (Pubitemid 36315558)
20. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbuerger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521.
21. Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, Kotani K, Islam A, Keno Y, Kobatake T, Nagai Y, Fujioka S, Tarui S, Matsuzawa Y. Contribution of visceral fat accumulation to the development of coronary-artery disease in nonobese men. Atherosclerosis 1994; 107: 239-246. (Pubitemid 24206863)
22. Gohda T, Gotoh H, Tanimoto M, Sato M, Io H, Kaneko K, Hamada C, Tomino Y. Relationship between abdominal fat accumulation and insulin resistance in hemodialysis patients. Hypertens Res 2008; 31: 83-88. (Pubitemid 351325619)
23. Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O'Donnell CJ, Fox CS, Hoffmann U. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 2009; 30: 850-856.
24. Ohkawa S, Odamaki M, Ikegaya N, Hibi I, Miyaji K, Kumagai H. Association of age with muscle mass, fat mass and fat distribution in non-diabetic haemodialysis patients. Nephrol Dial Transpl 2005; 20: 945-951. (Pubitemid 40704031)
25. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81. (Pubitemid 36842239)
26. Koh KK, Quon MJ, Han SH, Chung WJ, Kim JA, Shin EK. Vascular and metabolic effects of candesartan: insights from therapeutic interventions. J Hypertens 2006; 24: S31-S38. (Pubitemid 44336821)
27. Nomura S, Inami N, Kimura Y, Omoto S, Shouzu A, Nishikawa M, Iwasaka T. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 2007; 21: 38-44. (Pubitemid 44929342)
28. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717-1724. (Pubitemid 44684802)
29. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thone-Reineke C, Unger T, Kintscher U. PPAR gamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143. (Pubitemid 40946504)
30. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T. Azelnidipine a newly developed longacting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004; 43: 724-730. (Pubitemid 38534074)
31. Nakamura T, Kodama Y, Takano H, Umetani K, Fujioka D, Saito Y, Kawabata KI, Obata JE, Kitta Y, Kobayashi T, Mende A, Kugiyama K. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 2007; 193: 449-451. (Pubitemid 47058110)
32. Saito S, Fujiwara T, Matsunaga T, Minagawa K, Fukui K, Fukuda I, Osanai T, Okumura K. Increased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: a role of the attenuation of oxidative stress. Atherosclerosis 2008; 199: 378-383.
33. McNeill AM, Schmidt MI, Rosamond WD, East HE, Girman CJ, Ballantyne CM, Golden SH, Heiss G. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-390. (Pubitemid 40170944)
34. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held PJ. The dialysis outcomes and practice patterns study (DOPPS): an international hemodialysis study. Kidney Int 2000; 57: S74-S81.